Welcome to our dedicated page for Kintara Therapeutics news (Ticker: KTRA), a resource for investors and traders seeking the latest updates and insights on Kintara Therapeutics stock.
Kintara Therapeutics, Inc. (KTRA) is a clinical-stage biopharmaceutical company pioneering targeted therapies for solid tumor cancers, with a focus on its proprietary photodynamic technology platform. This page serves as the definitive source for verified news and press releases related to KTRA's research advancements, regulatory milestones, and corporate developments.
Investors and industry professionals will find timely updates on clinical trial progress, including details about the company's lead program REM-001 Therapy for cutaneous metastatic breast cancer. The repository also features announcements regarding strategic partnerships, financial disclosures, and scientific presentations – all essential for understanding KTRA's position in the oncology therapeutics landscape.
Content highlights include coverage of pipeline developments, FDA communications, and collaborative research initiatives. Each update is curated to provide clear context about how new information aligns with the company's mission to address unmet needs in cancer treatment through localized, light-activated therapies.
Bookmark this page for streamlined access to KTRA's latest developments, and check back regularly for objective reporting on innovations in photodynamic therapy and solid tumor treatment strategies.
Kintara Therapeutics (KTRA) has entered into agreements to raise approximately $15 million through a registered direct offering of 12 million shares of common stock and warrants priced at $1.25 per share. The offering is expected to close around September 28, 2021. Proceeds will fund clinical studies, working capital, and potential acquisitions. H.C. Wainwright & Co. is the exclusive placement agent. The securities are offered under a shelf registration statement filed with the SEC.
Kintara Therapeutics (Nasdaq: KTRA) announced topline data from its Phase 2 clinical study of VAL-083 for newly-diagnosed glioblastoma multiforme (GBM) patients, which shows promising results. In the study, 36 efficacy evaluable patients exhibited a median progression-free survival (PFS) of 10.0 months and median overall survival (mOS) of 16.5 months. Myelosuppression was reported as the most common adverse effect, with one serious adverse event noted. VAL-083, a first-in-class treatment, continues to be evaluated as a potential breakthrough therapy for GBM patients.
Kintara Therapeutics (KTRA) announced the activation of the VAL-083 treatment arm in the registrational Phase 2/3 clinical trial for glioblastoma multiforme (GBM) as of August 16, 2021. The GBM AGILE trial aims to evaluate multiple therapies at over 40 sites in the U.S. and Canada, potentially expanding to 65 sites globally. The trial is expected to expedite VAL-083's regulatory submission by up to 18 months, supported by a cost-sharing model. VAL-083 is designed to overcome MGMT resistance and has shown promise in various oncology indications.
Kintara Therapeutics (Nasdaq: KTRA) will have CEO Saiid Zarrabian present at the Investor Summit Conference on August 17, 2021, at 12:30 p.m. ET. The company focuses on developing novel cancer therapies for patients resistant to existing treatments, with two Phase 3-ready therapeutics: VAL-083 for glioblastoma and REM-001 for cutaneous metastatic breast cancer. Kintara boasts an 80% complete response rate for REM-001 in clinical trials. Investors interested in one-on-one meetings can register for the event online.
Kintara Therapeutics (Nasdaq: KTRA) will present at the BTIG Virtual Biotechnology Conference on August 9, 2021, at 2:00 p.m. ET. CEO Saiid Zarrabian will deliver a corporate presentation, followed by opportunities for one-on-one meetings. Kintara focuses on developing innovative cancer therapies, with two Phase 3-ready candidates: VAL-083 for glioblastoma and REM-001 for cutaneous metastatic breast cancer. VAL-083 is a first-in-class therapy showing promise in various cancers, while REM-001 has demonstrated an 80% complete response rate in prior studies. For more details, visit www.kintara.com.
Kintara Therapeutics (Nasdaq: KTRA) announced topline results from the recurrent arm of its Phase 2 clinical trial for VAL-083 at MD Anderson Cancer Center. The trial included 89 patients with glioblastoma multiforme, showing a median overall survival (mOS) of 8.0 months for those on a 30 mg/m2/day dose, outperforming historical data for lomustine at 7.2 months. While myelosuppression was noted as a common adverse event, the results indicated VAL-083's potential in treating this challenging cancer type, with further studies planned under the GBM AGILE program.
Kintara Therapeutics (Nasdaq: KTRA) announced its addition to the Russell Microcap Index, effective June 28, 2021. This milestone is expected to enhance investor exposure to Kintara's mission of developing innovative cancer therapies. The company is advancing its lead product, VAL-083, in the GBM AGILE study for glioblastoma. Inclusion in the Russell Microcap Index provides automatic membership in growth and value style indexes, crucial as over $10.6 trillion in assets benchmark against Russell's U.S. indexes.
Kintara Therapeutics (Nasdaq: KTRA) announced the enrollment of the final patient in the adjuvant arm of its Phase 2 clinical study for VAL-083 at MD Anderson Cancer Center. This trial focuses on newly-diagnosed glioblastoma multiforme patients, replacing standard care temozolomide. The study aims to evaluate whether VAL-083 improves overall survival, using 36 patients. VAL-083 has received multiple designations from FDA and EMA, including Orphan Drug Designation for GBM. The company is also advancing its REM-001 therapy platform for metastatic breast cancer.
Kintara Therapeutics (Nasdaq: KTRA) announced that CEO Saiid Zarrabian will present a corporate overview at the LD Micro Virtual Invitational Conference from June 8-10, 2021. His presentation is scheduled for June 9 at 2:30 pm ET, Track 1. Kintara specializes in developing novel cancer therapies, including VAL-083 for glioblastoma multiforme and REM-001 for cutaneous metastatic breast cancer. VAL-083 has shown clinical activity in several cancers, while REM-001 has an 80% complete response rate in prior trials. Investors can register for the conference here.
Kintara Therapeutics (Nasdaq: KTRA) announced the activation of its VAL-083 treatment arm in the Global Coalition for Adaptive Research's registrational Phase 2/3 clinical trial for glioblastoma multiforme (GBM), with 15 U.S. sites active as of May 14, 2021. The GBM AGILE trial aims to enroll 150-200 patients and could expedite VAL-083's pivotal trial completion by 18 months. VAL-083 is a first-in-class treatment and may redefine therapy for various GBM subtypes. The company is focused on advancing VAL-083 alongside its REM-001 therapy for metastatic breast cancer.
FAQ
What is the current stock price of Kintara Therapeutics (KTRA)?
What is the market cap of Kintara Therapeutics (KTRA)?
